Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5.
BUPIVACAINE LIPOSOME vs LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine liposome is a long-acting local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx through voltage-gated sodium channels in neuronal cell membranes. The liposomal formulation provides sustained release of bupivacaine, prolonging analgesic effect.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking the initiation and conduction of nerve impulses. Dextrose provides caloric support.
Local infiltration: up to 266 mg (20 mL of 1.3% or 10 mL of 2.66%) single dose; interscalene brachial plexus block: up to 133 mg (10 mL of 1.3%) single dose; sciatic nerve block in the popliteal fossa: up to 133 mg (10 mL of 1.3%) single dose; adductor canal block: up to 133 mg (10 mL of 1.3%) single dose; max dose 266 mg per procedure.
For IV administration, typical adult dose is 5-7 mg/kg intravenously as a single bolus, followed by 0.5-1 mg/kg every 5-10 minutes as needed, up to a maximum total dose of 200-300 mg. For epidural or caudal anesthesia, 15-20 mL of the 5% solution provides adequate block. For peripheral nerve block, 10-30 mL. Do not exceed 5 mg/kg per dose intravenously or 300 mg per dose by infiltration.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours (mean 18 hours) due to prolonged release from liposomal depot; significantly longer than conventional bupivacaine (2-4 hours), reflecting slow absorption rate-limited elimination.
Terminal elimination half-life is approximately 1.5 to 2 hours in healthy adults after intravenous administration. In patients with heart failure or hepatic impairment, half-life may be prolonged to 4-6 hours or more. After epidural administration, half-life may be slightly longer due to ongoing absorption.
Primarily hepatic metabolism to 3-hydroxybupivacaine and desbutylbupivacaine; renal excretion of metabolites accounts for ~95% of elimination, with <5% unchanged drug excreted in urine; biliary/fecal excretion minimal (<5%).
Renal excretion of unchanged lidocaine and metabolites; less than 10% excreted unchanged in urine. Hepatic metabolism produces active metabolites (MEGX, GX) which are renally excreted. Biliary/fecal excretion negligible.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)